The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis

• Published in: Scientific reports Vol. 10; no. 1; pp. 21355 - 9
• Main Authors: Lungulescu, Cristian Virgil, Ungureanu, Bogdan Silviu, Turcu-Stiolica, Adina, Ghimpau, Valentina, Artene, Stefan Alexandru, Cazacu, Irina Mihaela, Grecu, Alexandru Florian, Dinescu, Venera Cristina, Croitoru, Adina, Volovat, Simona Ruxandra
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.12.2020; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 692/4028; Antineoplastic drugs; Asthma; Cetuximab - adverse effects; Cytotoxicity; Galactose; Galactose - immunology; Humanities and Social Sciences; Humans; Hypersensitivity; Immunoglobulin E; Immunoglobulin E - immunology; Immunotherapy; Inflammatory bowel diseases; Intestine; Meta-analysis; Monoclonal antibodies; multidisciplinary; Rheumatoid arthritis; Science; Science (multidisciplinary); Targeted cancer therapy
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-78497-7

Recombinant monoclonal antibodies are used for treating various diseases, from asthma, rheumatoid arthritis, and inflammatory bowel disease to cancer. Although monoclonal antibodies are known to have fewer toxic reactions compared with the conventional cytotoxic antineoplastic drugs, the cases of severe systemic hypersensitivity reaction (HSR) should be acknowledged. Our aim was to assess the diagnostic accuracy of the anti-IgE for galactose-α-1,3-galactose in patients with HSRs to cetuximab. We searched in PubMed, Cochrane Library, Scopus, and World of Science databases to July 1st, 2020. We included a total of 6 studies, with 1074 patients. Meta-analysis was performed using bivariate analysis and the random-effect model. The pooled sensitivity was 73% (95% CI 62–81%) and the pooled specificity was 88% (95% CI 79–94%). We had not found significant heterogeneity and, despite some discrepancies in the nature of data available in the analysed studies, we draw the conclusion that the presence of cetuximab specific IgE (anti cetuximab antibody) and/or galactose-α-1,3-galactose shows moderate to high sensitivity and specificity of developing an HSR. More studies are needed to establish a protocol necessary for the proper prediction and avoidance of HSR related to cetuximab.